(Q34095042)

31 July 2017

0 references

Vasospasm after aneurysmal subarachnoid hemorrhage: review of randomized controlled trials and meta-analyses in the literature (English)

1 reference

aneurysmal subarachnoid hemorrhage

31 July 2017

0 references

1 reference

3

J D Mocco

1 reference

31 July 2017

4

Brian L Hoh

1 reference

31 July 2017

Gregory J Velat

1

1 reference

31 July 2017

Matthew M Kimball

series ordinal

2

1 reference

31 July 2017

language of work or name

1 reference

1 November 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

76

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

446-454

1 reference

Cerebral Arterial Spasm – A Controlled Trial of Nimodipine in Patients with Subarachnoid Hemorrhage

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Effects of a hydroxyl radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: results of a multicenter, placebo-controlled double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Magnesium: a useful adjunct in the prevention of cerebral vasospasm following aneurysmal subarachnoid haemorrhage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Cerebral Vasospasm with Ruptured Saccular Aneurysm — The Clinical Manifestations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

The International Cooperative Study on the Timing of Aneurysm Surgery. The North American experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Effect on cerebral vasospasm of coil embolization followed by microcatheter intrathecal urokinase infusion into the cisterna magna: a prospective randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Cerebral vasospasm after subarachnoid hemorrhage: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Metaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Cost-effectiveness analysis of nimodipine treatment after aneurysmal subarachnoid hemorrhage and surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage : a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Clinical course of spontaneous subarachnoid hemorrhage: a population-based study in King County, Washington

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Prediction and prevention of delayed ischemic dysfunction after aneurysmal subarachnoid hemorrhage and early operation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Early intervention with nimodipine in subarachnoid haemorrhage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Calcium antagonists for aneurysmal subarachnoid haemorrhage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Control of hypertension and prophylaxis against vasospasm in cases of subarachnoid hemorrhage: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Declining mortality from subarachnoid hemorrhage: changes in incidence and case fatality from 1985 through 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Magnesium infusion for vasospasm prophylaxis after subarachnoid hemorrhage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa stu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: a prospective randomized pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.02.030

10.1016/J.WNEU.2011.02.030

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference